Acronym:
CA224-047
ACTRN/NCT /ethics:
Scientific title:
Summary of trial and patient characteristics
Cancer Type | Melanoma & other skin | ||
---|---|---|---|
Trial Type | Treatment | ||
Phase | Phase II, Phase III | Tumour Stream | Melanoma |
Age Range | 18 years and older | Cancer Stage | Metastatic or Widespread |
Sex | Both | Anticipated Start Date | |
Molecular Target | Anticipated End Date |
Cancer Type | Melanoma & other skin |
---|---|
Trial Type | Treatment |
Phase | Phase II, Phase III |
Age Range | 18 years and older |
Sex | Both |
Molecular Target | |
Tumour Stream | Melanoma |
Cancer Stage | Metastatic or Widespread |
Anticipated Start Date | |
Anticipated End Date |
Trial Summary
A randomized, double-blind phase 2/3 study of Relatlimab combined with Nivolumab versus Nivolumab in participants with previously untreated metastatic or unresectable melanoma.
Lay Summary
Sponsor / Cooperative group
Participating Hospitals
Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
---|---|---|---|---|---|
Flinders Medical Centre | Alex Scott-Hoy | alex.scott-hoy@sa.gov.au | 08 8204 4830 | Amitesh Roy | Recruiting |